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Background: γ-tocotrienol (GT3), an analogue of vitamin E, has gained increasing scientific interest recently as it
provides significant health benefits. It has been shown that emulsified GT3, after subcutaneous administration, has
long-term biological effects. However, whether the effects are due to the increase of GT3 level in the early phase
following administration or the persistent functions after accumulation in tissues is unknown. This study was
conducted to determine the levels of GT3 in different tissues by high performance liquid chromatography (HPLC)
with a fluorescence detector after a single-dose of GT3 with polyethylene glycol (PEG-400) emulsion via
subcutaneous injection. Previous studies have explored that GT3 has favorable effects on bone and can inhibit
osteoclast formation. To confirm the persistent biological activity of accumulated GT3 in tissues, receptor activator
of NF-κB ligand (RANKL) and osteoprotegerin (OPG) gene expressions, which have an important role in regulating
osteoclast formation, were also evaluated in bone tissue on day 1, 3, 7 and 14 after a signal subcutaneous injection
of GT3.
Methods: C57BL/6 female mice were administrated GT3 (100 mg/kg body weight) with PEG-400 emulsion by
subcutaneous injection. GT3 levels in different tissues were determined by HPLC with a fluorescence detector.
Gene expressions were measured by real-time PCR.
Results: GT3 predominantly accumulated in adipose and heart tissue, and was maintained at a relatively stable
level in bone tissues after a single-dose administration. Accumulated GT3 in bone tissues significantly inhibited the
increase in RANKL expression and the decrease in OPG expression induced by db-cAMP.
Conclusions: We investigated the tissue distribution of GT3 with PEG emulsion by subcutaneous administration,
which has never been reported so far. Our results suggest that GT3 with PEG emulsion accumulated in tissues is
able to carry out a long-term biological effect and has therapeutic value for treating and preventing osteoporosis.Background
Vitamin E, one of the essential micronutrients and a
known antioxidant, includes two groups of closely re-
lated fat-soluble compounds, the tocopherols and toco-
trienols, each with the four analogues, α, β, γ, and δ.
These isoforms differ in the saturation of their side
chains and both the number of methyl substituents and
their positions in the chromanol ring [1,2].
For the most part, early antioxidant studies focused on α-
tocopherol, the predominant form of vitamin E existing in* Correspondence: fuqiang@jsinm.org
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unless otherwise stated.human and animal tissues. Based on epidemiologic and
retrospective studies, supplementation with Vitamin E
(mainly α-tocopherol) is considered to be a nutrition-based
strategy to prevent diseases and to support healthy aging.
However, a new study in mice showed that α-tocopherol
can stimulate bone osteoclast fusion independent of its
antioxidant activity, resulting in increased bone resorption
[3]. The results from that study raise a question of whether
vitamin E (mainly α-tocopherol) taken as dietary supple-
ment is suitable considering it may have a risk of
osteoporosis.
On the other hand, tocotrienols have gained increasing
scientific interest during recent years as they have been
reported to possess certain biology activities that weretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Deng et al. Lipids in Health and Disease 2014, 13:66 Page 2 of 7
http://www.lipidworld.com/content/13/1/66not observed in tocopherols [4]. This is especially true
for γ-tocotrienol (GT3), which is abundant in palm oil
and rice bran [5,6], as it provides significant health bene-
fits, including anticancer [7-10], anticholesterolemic
[11,12], antihypertensive [13], and antiatherosclerotic ef-
fects [14], as well as acting as a potent antioxidant
[15,16]. Moreover, GT3 is a particularly potent radio-
prophylactic agent in vivo [17] and has favorable effects
on bone [18]. All of these studies have shown γ-
tocotrienol health benefits to be significantly greater
than those of α-tocopherol.
Despite the growing interest in GT3, there is a paucity of
information about bioavailability and there is still much
controversy about its absorption, retention, and metabol-
ism. α-tocopherol is preferentially incorporated into very
low-density lipoproteins and transported to various tissues
by lipoprotein because of its high affinity for α-tocopherol
transfer protein (α-TTP) [19]. In contrast, the absorption of
tocotrienols has been found to be low and incomplete by
oral administration [20]. The presence of a transfer protein
that preferentially selects α-tocopherol seems to explain
why all other forms of vitamin E have a lower biological ac-
tivity compared with α-tocopherol. Therefore, oral adminis-
tration is unsuitable for GT3 biological activity studies
in vivo.
In the previous studies of radioprotection, we found that
administration of a single-dose of GT3 with polyethylene
glycol (PEG-400) emulsion by subcutaneous injection could
ameliorate radiation injury, including radiation-induced
vascular oxidative stress, gastrointestinal injury, protection
of hematopoietic stem and progenitor cells depletion, and
induction of cytokines production. These effects led to en-
hancement of hematopoietic recovery and improvement of
30-day survival after total body irradiation (TBI) [21-23].
These results suggested that administration of emulsified
GT3 by subcutaneous injection has long-term biological ef-
fects; however, whether the biological effects are due to the
increase of GT3 level in the early phase or the persistent
functions as the accumulation in tissues is unknown.
Therefore, it is necessary to investigate the biodistribution
of emulsified GT3 and the duration of biological activity
in vivo after a single-dose of GT3 administration.
Receptor activator of NF-κB ligand (RANKL) is a
member of the tumor necrosis factor (TNF) family of cy-
tokines and is expressed by stromal/osteoblast, hyper-
trophic chondrocytes, osteocytes and other cell types,
including T and B lymphocytes [24]. Binding of RANKL
to its receptor RANK triggers the activation of multiple
downstream signaling which regulates osteoclast forma-
tion, activation and survival in normal bone modeling
and remodeling [25]. Osteoprotegerin (OPG) is a soluble
decoy receptor for RANKL that blocks ligand binding to
RANK, thereby preventing the signaling required for
osteoclast differentiation and activation [26]. The relativeconcentration of RANKL and OPG in bone is a major
determinant of bone mass and the RANKL/RANK/OPG
system is critical for skeletal health, disruption of this
system leads to or causes numerous bone diseases [27].
Previous studies have reported that γ-tocotrienol can in-
hibit osteoclast formation and improve normal bone
structure [28,29].
In this study, we determined the durative levels of GT3
in different tissues by high performance liquid chromatog-
raphy (HPLC) with a fluorescence detector after adminis-
tration of a single-dose of GT3 with polyethylene glycol
(PEG-400) emulsion by subcutaneous injection. In addition,
we also investigated the persistent biological activity of ac-
cumulated GT3 by examining RANKL and OPG gene ex-
pression in bone tissues at various time intervals following
db-cAMP administration.
Results
Previous studies have detected GT3 levels by oral adminis-
tration or dietary intake [30-32]. The GT3 levels in tissues
of SD rats by intragastric administration has also been re-
ported [33]. However, the distribution of GT3 in various
tissues by subcutaneous administration has not been inves-
tigated. In the present study, we determined the tissue dis-
tribution of GT3 via this administration route by high
performance liquid chromatography (HPLC).
Silica normal-phase column chromatography can separ-
ate all eight tocopherols and tocotrienols and is the most
available HPLC method for GT3 detection in plants and
food which originated from plants [6,34,35]. However, octa-
decylsilyl (ODS) columns are widely used for LC separation;
and reversed-phase methods are usually preferred over the
normal-phase methods. As GT3 is the sole vitamin E
analogue in our experimental samples, a reversed-phase
HPLC method with a fluorescence detector was utilized for
GT3 analysis in our study.
In order to calculate the recovery of extraction of GT3,
2,2,5,7,8-pentamethyl-6-chroman (PMC) was used as an in-
ternal standard as introduced by Ueda and Igarashi [36].
The calibration curves of both GT3 and PMC were linear
in the range with correlation coefficients (r) larger than
0.999 and regression equations of y = 33833x + 2753.6
and y = 28684x + 2030.2 for GT3 and PMC, respectively
(Figure 1). The detection limit of quantification was 0.1 ng,
which represents the lowest concentration in the calibra-
tion curves. Under the chromatographic conditions de-
scribed above, PMC and GT3 was eluted at 3.9 and
8.5 min, respectively. Since both PMC and GT3 were eluted
within a short time, the analytical run time was optimized
to 12 min, which is shorter than those of normal-phase
HPLC methods with a run time of at least 20 min [6,34,35].
Therefore, our results suggested that the reversed-phase
HPLC method was simple and fast, making it applicable for
routine analysis of GT3 in tissues.
Figure 1 Calibration curves and chromatograms. HPLC calibration curves and chromatograms of PMC (A) and GT3 standard sample (B).
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and serum were detected on day 3 and 14 after sub-
cutaneous injection of GT3 with PEG-400 emulsion.
Previous studies that detected GT3 levels after oral
administration or dietary intake in rats, mice, and
hamsters have shown that GT3 specifically accumu-
lated in skin and adipose tissue [30-32]. In our study,
GT3 was predominant in adipose tissue on day 3 and
was still higher on day 14 after administration of
a single-dose of emulsified GT3 by subcutaneousFigure 2 Histogram of tissue distribution of GT3. Histogram of tissue d
with PEG-400 emulsion. The level of control group was used as a baseline
value for the experiment groups (day 3 and day 14). *, P < 0.05 by Studentinjection (Figure 2). This is consistent with the stud-
ies in which GT3 was administered in the diet,
indicating that GT3 predominantly accumulates in
adipose tissue no matter what routes of administra-
tion were used. It is interesting to find that GT3
levels in heart and spleen significantly increased on
day 14 compared to the level on day 3 (Figure 2).
The increasing levels of GT3 in these tissues may be
due to these two organs having the advantage to re-
uptake GT3 from plasma after release from adiposeistribution of GT3 on day 3 and 14 after subcutaneous injection of GT3
value and the concentrations of GT3 were subtracted from baseline
’s t test compared with day 3.
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beneficial effects on the cardiovascular system and
spleen colony formation [22]. For bone tissues (femur
and spine), the GT3 level was relatively stable and
had no significant change (P > 0.05) from day 3 to
day 14 after administration (Figure 2).
Currently, there is still limited information available
regarding the metabolism of tocotrienols. Some studies
report that dietary tocotrienols are absorbed in the small
intestine and secreted with triacylglycerol-rich chylomi-
crons into the lymph and blood; then after that, the
absorbed tocotrienols are transported to the liver [37,38].
Our results indicate that GT3 levels in the liver are rela-
tively lower than in the heart, kidney and adipose tissue,
particularly on day 14 after subcutaneous delivery, im-
plying a possibility of liver-independent transport
of GT3 into the various tissues after subcutaneous
injection.
GT3 with PEG emulsion after subcutaneous administra-
tion has long-term biological effects (20–22); however, it isFigure 3 GT3 on RANKL and OPG gene expression. The effect of accum
by db-cAMP in bone tissues (spine and femur). Excipent (CON and CON + d
db-cAMP groups) with PEG-400 emulsion were subcutaneously injected on
indicated in figures, mice were injected intraperitoneally with db-cAMP (10
total volume of 100 μL or phosphate-buffered saline (PBS, CON and GT3 gr
CON group. Each bar represents the mean ± STDEV of eight mice. *, P < 0.0not clear whether the durative biological effects are the re-
sult of the rapid increase in GT3 level in the early phase
after administration or the accumulation of GT3 in tissues.
As GT3 level was relatively stable in bone tissues, to inves-
tigate whether accumulated GT3 still had biological effects
after a period of time, RANKL and OPG mRNA expression
were examined. RANKL and OPG are both produced by
osteoblastic cells and are indicative of osteoclastogenesis
stimulation and inhibition respectively. In vivo, RANKL ex-
pression is up-regulated in bone and lymphoid tissues after
administration of db-cAMP, a cell permeable analogue of
cAMP [39]. Our results showed that RANKL was increased
and OPG was decreased in mRNA levels after administra-
tion of db-cAMP; accumulated GT3 in bone tissues inhib-
ited RANKL expression and blocked the down-regulation
of OPG, even on day 14 after the single-dose of emulsified
GT3 supplementation (Figure 3). Although the reduction
of OPG expression on day 14 appeared to lessen, the data
still suggested that emulsified GT3 has persistent biological
effects after accumulation in tissues.ulated GT3 on expression of RANKL (A) and OPG (B) gene stimulated
b-cAMP groups) or GT3 (100 mg/kg body weight, GT3 and GT3+
day 0. One hour before mice were sacrificed at the time point of the
0 mg/kg body weight, CON + db-cAMP and G + db-cAMP groups) in a
oups). Expression in other groups was normalized to expression in
5 by one-way ANOVA followed by Tukey’s post hoc test.
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more potent antioxidative, anti-hypercholesterolemic, and
anticancer than tocopherols, suggesting that GT3 has sig-
nificant health benefits. However, the absorption of toco-
trienols was found to be low and incomplete via the oral
route and only approximately 9% bioavailability can be ob-
served in vivo [20]. Therefore, it is necessary to explore
other methods of administration to improve biological ac-
tivity in vivo. Fat soluble vitamins including GT3 are better
absorbed in the presence of surfactants or from emulsified
vehicles. Thus, there is increased interest in the use of self-
emulsifying systems in which lipophilic drugs such as GT3
may be stored in concentrated oil-surfactant solution to be
reconstituted with water to form an emulsion immediately
before use [40]. In our study, we utilized polyethylene glycol
(PEG-400) as the emulsifier and such self-emulsifying sys-
tem has been approved that can achieve a faster rate and
higher extent of absorption.
Conclusions
In the present study, we investigated the tissue distribution
of GT3 (packed with PEG emulsion) after subcutaneous ad-
ministration, which has never been reported so far. We
found that GT3 predominantly accumulated in adipose tis-
sue and heart; and was maintained at a relatively stable level
in bone tissues after a single-dose administration. Further-
more, we also demonstrated that emulsified GT3 has a
long-term biological activity after accumulation in tissues
via subcutaneous injection. GT3 inhibited RANKL up-
regulation and blocked OPG down-regulation which pre-
vents bone loss. These results suggested that emulsified
GT3 has significant health benefits and may have thera-
peutic value for treating and preventing osteoporosis.
Methods
Materials
GT3 (a kind gift of M. Hauer-Jensen) was obtained from
Yasoo Health Inc. (Johnson City, TN). Shortly before ad-
ministration, GT3 was dispersed in a mixture of PEG-400
(Sigma, St. Louis, MO). 2,2,5,7,8-pentamethyl-6-chroman
(PMC) as an internal standard for HPLC was purchased
from Sigma. Hexane (Tedia Company Inc, USA), alcohol
(Tedia Company Inc, USA), methanol (Merk KGaA,
Germany), acetonitrile (Tedia Company Inc, USA) and
methylene chloride (Merk KGaA, Germany) were of HPLC
grade. Dibutyryl-cAMP (db-cAMP) was purchased from
Sigma. All other reagents and chemicals were commercially
available extra-pure-grade products.
Animals
The experimental protocol was reviewed and approved
by the Institutional Animal Care and Use Committees
(IACUC) of Jiangsu Institute of Nuclear Medicine
(JSINM2010007).C57BL/6 female mice (Eight-week-old, about 23 ~
25 g) were purchased from SLAC laboratory animals
Lit. (Shanghai, China). They were housed under stan-
dardized conditions with controlled temperature and
humidity and a 12-12-h day-night light cycle. Mice
were given free access to a vitamin E-free diet and
water.
Tissue distribution of GT3 by HPLC
After acclimatizing for one week, mice were administrated
GT3 (100 mg/kg body weight) with PEG-400 emulsion or
excipient (olive oil) by subcutaneous injection. Eight mice
for each treatment group were euthanized on day 3 and 14
after administration of emulsified GT3 or excipient. Blood
samples were collected into heparinized tubes and directly
centrifuged at 5000 × g for 10 min to separate the plasma
or collected into normal tubes to separate serum. After
blood collection, the heart, liver, spleen, lung, kidney, thy-
mus, small intestine, brain, spine, femur, muscle, and adi-
pose tissue were immediately harvested. All samples were
stored at −80 °C until analysis.
GT3 was extracted by following method. For blood sam-
ples, 500 μL plasma or serum was added to test tubes con-
taining 500 μL SDS (0.05 M), 1 mL alcohol (90.2% ethanol,
4.9% methanol, and 4.9% isopropanol), and 0.01 g pyrogal-
lol with 1 μg 2,2,5,7,8-pentamethyl-6-chroman (PMC) as
an internal standard. Next, 2 mL of hexane was added to
the mixture and vortex-mixed thoroughly. The mixture
was then centrifuged at 4000 × g for 10 min. For other tis-
sues, about 0.1 g of each sample was homogenized with
2 mL alcohol containing 0.02 g pyrogallol and 1 μg PMC.
Then, 200 μL potassium hydroxide (800 g/L) was added
and incubated in 70°C water bath for 30 min. After saponi-
fication, the tubes were placed on ice for 5 min, followed by
the addition of 2 mL hexane and shaken vigorously for
2 min and then centrifuged at 1500 × g for 10 min. After
drying the supernatant under an N2 gas flow, the residue
was dissolved in 100 μL ethanol.
The instrument used for HPLC was a Waters 6000
Controller with Waters 2475 multi λ fluorescence de-
tector (excitation 298 nm, emission 325 nm). The analyt-
ical column used was a C18 reverse-phase column
(250 × 4.6 mm, Inertsil, ODS-3; GL Science). The mobile
phase consisted of methanol, acetonitrile and methylene
chloride (50: 44: 6, v/v/v) with a flow rate of 1 mL/min.
The injection volume was 10 μL.
Gene expression analysis
Mice received a single-dose of GT3 (100 mg/kg body
weight) with PEG-400 emulsion (GT3 group) or excipient
alone (vehicle group) by subcutaneous injection. One hour
before being sacrificed, both GT3 and vehicle group mice
were injected intraperitoneally with db-cAMP (100 mg/kg
body weight) in a total volume of 100 μL or phosphate-
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sacrificed for each group on day 1, 3, 7 and 14; spine and
femur were harvested. The expressions of RANKL and
OPG induced by db-cAMP were measured by real-time
PCR.
Total RNA was purified by using Ultraspec reagent
(Biotecx Laboratories, Houston, TX) according to the
manufacturer’s instructions. Murine RANKL, OPG and
the housekeeping gene ribosomal protein S2 were ampli-
fied from the first-stand cDNA by using Taqman
quantitative PCR master Mix (Applied Biosystems). The
TaqMan assay numbers of the primer/probe sets used are:
RANKL, Mm00441908m1; OPG, Mm00435452m1; riboso-
mal protein S2 (forward, 5’-CCCAGGATGGCGACGAT-
3’; reverse, 5’-CCGAATGCTGTAATGGCGTAT-3’; probe,
FAM-5’-TCCAGAGCAGGATCC-3’-NFQ). PCR amplifica-
tion and detection were carried out on an ABI Prism 7500
Sequence Detecction System (Applied Biosystems) accord-
ing to the manufacturer’s instructions. Relative mRNA
levels were calculated using the ΔCt method [41]. All
mRNA levels are normalized to ribosomal protein S2
mRNA levels.Statistical analysis
Data are presented as the group means ± STDEV. A statis-
tical analysis was performed by using Student's t test for
two different groups or one-way ANOVA followed by
Tukey’s post hoc test for multiple comparisons. P < 0.05 is
considered to indicate a significant difference. All data were
analyzed using SPSS 17.0.Competing interests
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